CYCC
Price
$7.95
Change
-$0.94 (-10.57%)
Updated
Aug 15 closing price
Capitalization
12.63M
NGENF
Price
$2.12
Change
-$0.08 (-3.64%)
Updated
Aug 15 closing price
Capitalization
152.72M
Interact to see
Advertisement

CYCC vs NGENF

Header iconCYCC vs NGENF Comparison
Open Charts CYCC vs NGENFBanner chart's image
Cyclacel Pharmaceuticals
Price$7.95
Change-$0.94 (-10.57%)
Volume$208K
Capitalization12.63M
NervGen Pharma
Price$2.12
Change-$0.08 (-3.64%)
Volume$49.87K
Capitalization152.72M
CYCC vs NGENF Comparison Chart in %
Loading...
CYCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NGENF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYCC vs. NGENF commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYCC is a Hold and NGENF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (CYCC: $7.95 vs. NGENF: $2.12)
Brand notoriety: CYCC and NGENF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYCC: 6% vs. NGENF: 28%
Market capitalization -- CYCC: $12.63M vs. NGENF: $152.72M
CYCC [@Biotechnology] is valued at $12.63M. NGENF’s [@Biotechnology] market capitalization is $152.72M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYCC’s FA Score shows that 0 FA rating(s) are green whileNGENF’s FA Score has 0 green FA rating(s).

  • CYCC’s FA Score: 0 green, 5 red.
  • NGENF’s FA Score: 0 green, 5 red.
According to our system of comparison, NGENF is a better buy in the long-term than CYCC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYCC’s TA Score shows that 5 TA indicator(s) are bullish while NGENF’s TA Score has 3 bullish TA indicator(s).

  • CYCC’s TA Score: 5 bullish, 5 bearish.
  • NGENF’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CYCC is a better buy in the short-term than NGENF.

Price Growth

CYCC (@Biotechnology) experienced а -9.45% price change this week, while NGENF (@Biotechnology) price change was -4.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.94%. For the same industry, the average monthly price growth was +21.39%, and the average quarterly price growth was +21.23%.

Industries' Descriptions

@Biotechnology (+5.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NGENF($153M) has a higher market cap than CYCC($12.6M). NGENF YTD gains are higher at: -2.752 vs. CYCC (-91.190). NGENF has more cash in the bank: 14.6M vs. CYCC (93K). CYCC has less debt than NGENF: CYCC (9K) vs NGENF (81.8K).
CYCCNGENFCYCC / NGENF
Capitalization12.6M153M8%
EBITDAN/A-25.94M-
Gain YTD-91.190-2.7523,313%
P/E Ratio0.00N/A-
RevenueN/A0-
Total Cash93K14.6M1%
Total Debt9K81.8K11%
FUNDAMENTALS RATINGS
CYCC vs NGENF: Fundamental Ratings
CYCC
NGENF
OUTLOOK RATING
1..100
5052
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
95
Overvalued
PROFIT vs RISK RATING
1..100
10085
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9665
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
4050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYCC's Valuation (84) in the Biotechnology industry is in the same range as NGENF (95) in the null industry. This means that CYCC’s stock grew similarly to NGENF’s over the last 12 months.

NGENF's Profit vs Risk Rating (85) in the null industry is in the same range as CYCC (100) in the Biotechnology industry. This means that NGENF’s stock grew similarly to CYCC’s over the last 12 months.

NGENF's SMR Rating (100) in the null industry is in the same range as CYCC (100) in the Biotechnology industry. This means that NGENF’s stock grew similarly to CYCC’s over the last 12 months.

NGENF's Price Growth Rating (65) in the null industry is in the same range as CYCC (96) in the Biotechnology industry. This means that NGENF’s stock grew similarly to CYCC’s over the last 12 months.

NGENF's P/E Growth Rating (100) in the null industry is in the same range as CYCC (100) in the Biotechnology industry. This means that NGENF’s stock grew similarly to CYCC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYCCNGENF
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
82%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
78%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
83%
Advances
ODDS (%)
Bullish Trend 26 days ago
82%
N/A
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 6 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
84%
Aroon
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
CYCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NGENF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IBIO0.68N/A
N/A
iBio
PPG111.80-0.15
-0.13%
PPG Industries
GEF67.58-0.52
-0.76%
Greif
AXL5.74-0.08
-1.37%
American Axle & Manufacturing Holdings
MIST1.70-0.04
-2.30%
Milestone Pharmaceuticals

CYCC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYCC has been loosely correlated with PROK. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CYCC jumps, then PROK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYCC
1D Price
Change %
CYCC100%
-10.57%
PROK - CYCC
57%
Loosely correlated
-2.48%
JSPR - CYCC
36%
Loosely correlated
+2.64%
MTVA - CYCC
26%
Poorly correlated
N/A
HOWL - CYCC
24%
Poorly correlated
+0.76%
RLYB - CYCC
22%
Poorly correlated
+10.62%
More

NGENF and

Correlation & Price change

A.I.dvisor tells us that NGENF and INO have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NGENF and INO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGENF
1D Price
Change %
NGENF100%
-3.77%
INO - NGENF
23%
Poorly correlated
N/A
CYCC - NGENF
23%
Poorly correlated
-10.57%
GLSI - NGENF
22%
Poorly correlated
+0.75%
ZLDPF - NGENF
22%
Poorly correlated
+4.52%
SLDB - NGENF
22%
Poorly correlated
-0.97%
More